Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results
- PMID: 30248343
- DOI: 10.1016/j.juro.2018.08.084
Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results
Abstract
Purpose: Vascular targeted photodynamic therapy with TOOKAD® is a new therapeutic option for localized prostate cancer management. The objectives of this study were to assess the feasibility of radical prostatectomy after vascular targeted photodynamic therapy and describe functional and oncologic outcomes.
Materials and methods: We retrospectively included in study 45 patients who underwent salvage radical prostatectomy after vascular targeted photodynamic therapy for recurrent prostate cancer at a total of 14 surgical centers in Europe between October 2008 and March 2017. Of the 42 radical prostatectomies performed 16 were robot-assisted, 6 were laparoscopic and 20 were open surgery. Primary end points were morbidity and technical difficulties. Secondary end points were early and intermediate postoperative functional and oncologic outcomes.
Results: Median operative time was 180 minutes (IQR 150-223). Median blood loss was 200 ml (IQR 155-363). According to the surgeons the surgery was easy in 29 patients (69%) and difficult in 13 (31%). Nerve sparing was feasible in 14 patients (33%). Five postoperative complications (12%) were found, including 2 Clavien I, 2 Clavien II and 1 Clavien IIIB complications. Of the cases 13 (31%) were pT3 and 21 (50%) were pT2c. Surgical margins were positive in 13 patients (31%). Prostate specific antigen was undetectable at 6 to 12 months in 37 patients (88%). Nine patients underwent complementary radiotherapy. Four patients had final prostate specific antigen greater than 0.2 ng/ml at a median followup of 23 months (IQR 12-36). At 1 year 27 patients (64%) were completely continent (no pads) and 10 (24%) had low incontinence (1 pad). Four patients (11%) recovered potency without treatment and 23 (64%) recovered potency with appropriate treatment.
Conclusions: Salvage radical prostatectomy after vascular targeted photodynamic therapy treatment was feasible and safe without difficulty for most of the surgeons.
Comment in
-
Editorial Comment.J Urol. 2019 Feb;201(2):320-321. doi: 10.1097/01.JU.0000553001.88842.32. J Urol. 2019. PMID: 30634363 No abstract available.
-
Editorial Comment.J Urol. 2019 Feb;201(2):321. doi: 10.1097/01.JU.0000553002.96465.38. J Urol. 2019. PMID: 30634364 No abstract available.
Similar articles
-
Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.World J Urol. 2015 Jul;33(7):965-71. doi: 10.1007/s00345-015-1493-8. Epub 2015 Jan 23. World J Urol. 2015. PMID: 25614256
-
Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches.J Urol. 2019 Oct;202(4):725-731. doi: 10.1097/JU.0000000000000327. Epub 2019 Sep 6. J Urol. 2019. PMID: 31075058
-
Preliminary analysis of the feasibility and safety of salvage robot-assisted radical prostatectomy after radiation failure: multi-institutional perioperative and short-term functional outcomes.J Endourol. 2011 Jun;25(6):1013-9. doi: 10.1089/end.2010.0564. Epub 2011 May 13. J Endourol. 2011. PMID: 21568696
-
Salvage Local Treatments After Focal Therapy for Prostate Cancer.Eur Urol Oncol. 2019 Sep;2(5):526-538. doi: 10.1016/j.euo.2019.03.008. Epub 2019 Apr 15. Eur Urol Oncol. 2019. PMID: 31412013 Review.
-
Positive surgical margins after radical prostatectomy: a systematic review and contemporary update.Eur Urol. 2014 Feb;65(2):303-13. doi: 10.1016/j.eururo.2013.07.039. Epub 2013 Aug 3. Eur Urol. 2014. PMID: 23932439 Review.
Cited by
-
Follow-up of vascular-targeted photodynamic therapy in a real-world setting.World J Urol. 2024 Jan 20;42(1):55. doi: 10.1007/s00345-023-04738-9. World J Urol. 2024. PMID: 38244089 Free PMC article.
-
Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches.Pharmaceutics. 2023 Jun 19;15(6):1767. doi: 10.3390/pharmaceutics15061767. Pharmaceutics. 2023. PMID: 37376215 Free PMC article. Review.
-
Salvage Radical Prostatectomy after Primary Focal Ablative Therapy: A Systematic Review and Meta-Analysis.Cancers (Basel). 2023 May 12;15(10):2727. doi: 10.3390/cancers15102727. Cancers (Basel). 2023. PMID: 37345064 Free PMC article. Review.
-
Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Front Oncol. 2022 Sep 23;12:980239. doi: 10.3389/fonc.2022.980239. eCollection 2022. Front Oncol. 2022. PMID: 36212416 Free PMC article. Review.
-
Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative?-a narrative review.Ann Transl Med. 2022 Jul;10(13):755. doi: 10.21037/atm-22-50. Ann Transl Med. 2022. PMID: 35957731 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

